Table of Content
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in biosimilars dealmaking
2.1. Introduction
2.2. Biosimilars partnering over the years
2.3. Most active biosimilars dealmakers
2.4. Biosimilars partnering by deal type
2.5. Biosimilars partnering by therapy area
2.6. Deal terms for biosimilars partnering
2.6.1 Biosimilars partnering headline values
2.6.2 Biosimilars deal upfront payments
2.6.3 Biosimilars deal milestone payments
2.6.4 Biosimilars royalty rates
Chapter 3 – Leading biosimilars deals
3.1. Introduction
3.2. Top biosimilars deals by value
Chapter 4 – Most active biosimilars dealmakers
4.1. Introduction
4.2. Most active biosimilars dealmakers
4.3. Most active biosimilars partnering company profiles
Chapter 5 – Biosimilars contracts dealmaking directory
5.1. Introduction
5.2. Biosimilars contracts dealmaking directory
Chapter 6 – Biosimilars dealmaking by technology type
Appendices
Appendix 1 – Biosimilars deals by company A-Z
Appendix 2 – Biosimilars deals by stage of development
Appendix 3 – Biosimilars deals by deal type
Appendix 4 – Biosimilars deals by therapy area
Deal type definitions
Further reading
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
?
Table of figures
Figure 1: Biosimilars partnering since 2010
Figure 2: Active biosimilars dealmaking activity since 2010
Figure 3: Biosimilars partnering by deal type since 2010
Figure 4: Biosimilars partnering by disease type since 2010
Figure 5: Biosimilars partnering by technology type since 2010
Figure 6: Biosimilars deals with a headline value
Figure 7: Biosimilars deals with an upfront value
Figure 8: Biosimilars deals with a milestone value
Figure 9: Biosimilars deals with a royalty rate value
Figure 10 Top biosimilars deals by value since 2010
Figure 11: Most active biosimilars dealmakers since 2010